In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2
- 30 September 2006
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 53 (3) , 273-284
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Inhibition of human leukemia xenograft in nude mice by adenovirus-mediated tissue inhibitor of metalloproteinase-3Leukemia, 2005
- Tissue Inhibitor of Metalloproteinase-3 Expression from an Oncolytic Adenovirus Inhibits Matrix Metalloproteinase Activity In vivo without Affecting Antitumor Efficacy in Malignant GliomaCancer Research, 2005
- TIMP‐3 and endocrine therapy of breast cancer: an apoptosis connection emergesThe Journal of Pathology, 2004
- Lung cancer * 9: Molecular biology of lung cancer: clinical implicationsThorax, 2003
- Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor modelBlood, 2002
- The Fas Signaling Pathway: More Than a ParadigmScience, 2002
- Fas receptor‐mediated apoptosis: a clinical application?The Journal of Pathology, 2001
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999
- TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3FEBS Letters, 1998
- Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4Oncogene, 1997